In the special “GENETIC INSTABILITY” of Swiss Oncology in Motion, Prof. Dr. med. Viola Heinzelmann-Schwarz (University Hospital Basel), Prof. Dr. med. Jens Huober (Canton Hospital St. Gallen), PD Dr. med. Aurelius Omlin (OnkoZentrum Zürich), Prof. Dr. med. Dr. phil. Andreas Wicki (University Hospital Zurich) and Prof. Dr. med. Wolfram Jochum (Cantonal Hospital St. Gallen) discussed the role of genetic instability in various tumor types, in particular ovarian and endometrial carcinomas, breast carcionoma, GI tumors, and prostate, urothelial, and renal cell carcinomas, and how it influences treatment options. The discussion will be led by Prof. em. Richard Herrmann, MD, Basel, moderated.
You May Also Like
- From Risk Identification to Anti-Inflammatory Intervention
Inflammation as a Treatment Goal in Its Own Right
- Psoriasis Research: What's in the Pipeline?
Highly selective oral TYK inhibitors in Phase III
- Cardiometabolism
Retatrutid and the TRIUMPH Program: The Triple Agonist on the Horizon
- Pediatric Retinoblastoma
The Tumor Microenvironment and Modern Eye-Sparing Therapies
- Adherence and management in asthma and COPD
Better to listen to the pharmacist
- Focus Update 2026
Echocardiography in Cardio-Oncology
- Physical activity with IBD
Sport is not murder, but it doesn’t help either
- White and Black Skin Cancer